Kromek Group plc (KRMKF) Q4 2026 Earnings Call Prepared Remarks Transcript

Kromek reported FY2026 revenue of £27.1 million, in line with market expectations, supported by 36% underlying business growth across Advanced Imaging and CBRN detection. Gross margin declined as high-margin enablement-contract revenue fell to £10 million from £16.5 million in FY2025, reflecting product-mix changes rather than deterioration in underlying margins. Management said it remains confident of delivering FY2027 results in line with market expectations.

Analysis

The key equity issue is not top-line growth but earnings quality: mix is shifting away from unusually profitable contract-related revenue toward product sales, so reported revenue growth may not translate into proportionate EBITDA or cash conversion. For a small-cap detector/imaging supplier, the market will likely require evidence that recurring product gross margins and manufacturing utilization can offset this normalization; otherwise, valuation upside is capped despite delivery against guidance. The next 1-3 months should focus on order intake, backlog conversion, working-capital consumption, and whether management quantifies FY27 margin progression rather than only reiterating revenue expectations.

CBRN demand has attractive 6-18 month structural support from defense, border-security, and critical-infrastructure procurement, but the revenue path is likely lumpy because awards, qualification cycles, and government acceptance testing are irregular. A larger defense prime or systems integrator can be a second-order beneficiary if Kromek's components gain deployment, while Kromek bears greater single-program concentration, inventory, and customer-timing risk. The immediate positive reaction should therefore be constrained unless contract wins carry disclosed value, delivery schedules, and margin characteristics.

Contrarian risk is that the market treats prior high-margin revenue as a temporary comparison distortion and looks through it; if underlying product growth sustains above 25% while gross margin stabilizes, operating leverage could emerge faster than consensus expects from a low fixed-cost base. Conversely, this thesis is falsified by FY27 guidance maintenance accompanied by falling gross margin, receivable/inventory build, delayed CBRN awards, or a need for additional capital. Given likely micro-cap liquidity and limited disclosure in the release, the appropriate posture is an event-driven watch rather than chasing a modestly positive earnings print.

Key Decisions for Investors

• Maintain a watchlist position only in KMK/KRMKF until the company discloses FY27 order book, cash balance, operating-cash-flow trajectory, and segment gross-margin outlook; initiate a long only if product-led growth remains above 20% and gross margin is stable sequentially. Size conservatively because liquidity and contract concentration can dominate fundamentals.
• For a 1-3 month catalyst trade, buy KMK only on a disclosed CBRN or advanced-imaging award with contract value, delivery timing, and funding source; target at least 2:1 upside/downside to a stop below the pre-award price. Do not treat management confidence alone as a catalyst.
• Use defense exposure through a liquid sector proxy such as ITA rather than shorting peers against KMK: the company-specific thesis depends on execution and procurement timing, while broad defense demand does not hedge the risk of product-mix-driven margin pressure.
• Set a downside alert for a FY27 gross-margin decline or material working-capital outflow at the interim update; either would indicate that revenue conversion is weaker than the growth narrative and would invalidate a long thesis before year-end.